# Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease

> **NCT06850597** · PHASE2 · RECRUITING · sponsor: **Medical University of Lodz** · enrollment: 30 (estimated)

## Conditions studied

- MCI
- MCI-AD, Early Stage Alzheimer's Disease
- Alzheimer's Disease

## Interventions

- **DRUG:** dimethyl fumarate

## Key facts

- **NCT ID:** NCT06850597
- **Lead sponsor:** Medical University of Lodz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-28
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06850597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06850597, "Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06850597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*